Tirzepatide 5mg

What is Tirzepatide 5mg?

Tirzepatide (5 mg) is a synthetic, long-chain 39-amino acid peptide currently under investigation for its dual activity across metabolic signaling pathways. It belongs to a class of multi-receptor agonist peptides and features a fatty-acid side chain that supports extended activity in laboratory research models. Tirzepatide for research has been examined in controlled experimental systems exploring glucose-related mechanisms, energy balance regulation, and receptor-mediated metabolic signaling pathways. With a molecular weight of approximately 4813.48 g/mol, this peptide is manufactured with high purity and verified using modern analytical methods to ensure structural consistency and reproducibility in laboratory settings. This research-grade peptide is available in various vial sizes (5 mg, 10 mg, etc.) to accommodate flexible experimental design requirements.

Product Specifications

• Product Name: Tirzepatide
• Synonyms: P1206, LY3298176, tirzepatida, tirzepatidum, OYN3CCI6QE
• CAS Number: 2023788-19-2
• Chemical Formula: C225H348N48O68
• Subscript Format: C₂₂₅H₃₄₈N₄₈O₆₈
• Molecular Weight: 4813.48 g/mol
• Sequence: Tyr-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-Aib-Leu-Asp-Lys(C20-linker)-Ile-Ala-Gln-Lys-Ala-Phe-Val-Gln-Trp-Leu-Ile-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH₂
• Structure Type: Long-chain incretin analog with fatty-acid linker
• Purity: ≥98% (research grade)
• Appearance: White to off-white lyophilized powder

What are the key features of Tirzepatide 5mg?

Tirzepatide 5mg is supplied in a lyophilized powder format to maintain stability and support accurate reconstitution. This peptide is typically provided in sealed sterile vials to accommodate various research needs. Tirzepatide is validated for high purity using accepted analytical standards such as HPLC and mass spectrometry. It is suitable for in-vitro and in-vivo research applications. Key features include:

• Lyophilized peptide supplied in sterile vials for precise reconstitution
• Verified by HPLC and mass spectrometry for purity and identity
• Fatty-acid-modified backbone for extended research activity
• Suitable for metabolic and endocrine research studies
• Available in multiple vial sizes (including the tirzepatide 10 mg peptide format) to accommodate various laboratory requirements
• For laboratory experimentation and/or in-vitro testing only; qualified and licensed professionals only

How is Tirzepatide 5mg synthesized?

Via solid-phase peptide synthesis (SPPS), a technique that enables precise amino acid sequence assembly. This method also incorporates the fatty-acid side chain, which is crucial for enhancing molecular stability and extending activity. After synthesis, tirzepatide undergoes purification by HPLC, followed by verification of its identity and molecular weight using mass spectrometry. The final product is lyophilized to ensure long-term stability and ease of handling during experimental use.

What is Tirzepatide 5mg being studied for? What are its possible benefits?

Tirzepatide has been studied in research models for its potential role in metabolic regulation and energy balance. This research-grade peptide is available in multiple vial sizes (5mg, 10mg, and higher) to accommodate various laboratory requirements. Research has focused on its effects on glucose-related pathways and metabolic signaling in preclinical models. The potential biological benefits of tirzepatide include:

• Observed changes in metabolic markers and energy utilization
• Studied for potential effects on lipid metabolism
• Influences on glucose utilization and insulin regulation

These findings are limited to preclinical research and experimental models. All observations are based on laboratory research, and no clinical benefits are confirmed.

How does Tirzepatide 5mg work in research studies?

In research studies, tirzepatide functions by interacting with two key hormone-related pathways. It is a dual-agonist peptide that may influence:

• GLP-1 receptor activation: Studied for potential effects on gastric clearance, insulin secretion signaling, and glucagon regulation
• GIP receptor activation: Studied for potential effects on postprandial insulin signaling, lipid metabolism regulation, and GLP-1 pathway enhancement

This synergistic combination of dual-agonism is under investigation to determine how it affects metabolic signaling, nutrient response, and energy balance markers. Research continues to explore how activating multiple metabolic pathways at once may improve metabolic function and insulin sensitivity in preclinical models. These effects are still under investigation, and findings are strictly based on laboratory experiments.

What dosing information exists for Tirzepatide 5mg?

Dosing information for tirzepatide 5mg is derived exclusively from preclinical and in-vitro models. Studies on tirzepatide in animal models have typically used doses in the range of 10 nmol/kg (molar concentration). Research studies have observed dose-dependent responses at various concentrations to examine metabolic pathways, signaling, and receptor activation.

How should Tirzepatide 5mg be stored and handled?

Store in a lyophilized form at –20°C or lower to preserve stability. It must be kept protected from moisture, heat, and light to prevent degradation. After reconstitution, it should be stored at 2–8°C and used promptly. Reconstituted solutions are typically stable for 7–14 days in a neutral pH buffer (pH 7.2–7.4). Aseptic technique is required during handling, including the use of sterile syringes, needles, and containers to maintain sterility and prevent contamination. Repeated freeze-thaw cycles should be avoided as they can compromise the peptide's stability.

Where can I read more research about Tirzepatide 5mg?

Researchers interested in learning more about tirzepatide can explore the following peer-reviewed sources:

1. Willard FS, Douros JD, Gabe MB, et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight. 2020;5(17):e140532. Published 2020 Sep 3. doi:10.1172/jci.insight.140532
2. Fisman EZ, Tenenbaum A. The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect. Cardiovasc Diabetol. 2021;20(1):225. Published 2021 Nov 24. doi:10.1186/s12933-021-01412-5
3. Coskun T, Sloop KW, Loghin C, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Mol Metab. 2018;18:3-14. doi:10.1016/j.molmet.2018.09.009

Compliance Statement

This product is intended for laboratory research use only and is not approved for human or veterinary use.